Prospective evaluation of the relationship between response and exposure of total and unbound erlotinib in non-small cell lung cancer patients
ConclusionThe lack of relationship between efficacy and exposure of total and unbound erlotinib demonstrates that the standard dose of 150 mg/day is sufficient for the treatment of NSCLC harboringEGFR-activating mutations, despite wide inter-individual variability in exposure and dose reduction.Clinical trials registration number: UMIN000012862.
Source: Cancer Chemotherapy and Pharmacology - Category: Cancer & Oncology Source Type: research
More News: Cancer | Cancer & Oncology | Chemotherapy | Clinical Trials | Drugs & Pharmacology | Lung Cancer | Non-Small Cell Lung Cancer | Skin | Tarceva | Toxicology